Some outcomes, like reduced risk of cardiovascular disease and increased chance of nausea, were expected. But others took researchers by surprise.

T he newest weight-loss drugs, Wegovy and Zepbound, are incredibly popular. But doctors are still learning about all of the ways they affect the body—both helpful and harmful—beyond reducing weight. In report published in Nature Medicine,

Weight-loss and diabetes drugs reduced the risk of developing Alzheimer’s, an independent study published Monday showed.The big pharma companies Novo Nordisk and Eli Lilly look to be the main benefactors of GLP-1 medications turning into a “catch-all pill,

In all, researchers found that people taking GLP-1 medications had lower risks for 42 health outcomes, including liver failure, lung failure, cardiac arrest, aspiration pneumonia and shock.

Demand for weight-loss medications sold under brand names such as Ozempic and Wegovy continues to surge, with a recent study reporting one in eight Americans has taken or is currently using the drugs to treat diabetes,

If successful, the result could be lower Medicare Part D prices for drugs used to create a variety of conditions, such as cancer, asthma, type 2 diabetes and weight loss - Ozempic, Rybelsus and Wegovy. Austedo and Austedo XR, used to treat Huntington’s disease.

Can weight loss drugs curb alcohol addictions? This Louisiana doctor is keeping an eye on new findings and emerging research.

A new study published in the Nature Medicine monthly journal highlights the benefits and risks of weight-loss drugs like Ozempic and Wegovy. Positives include reduced risks of infections and cardiac arrest,

The study revealed that weight-loss drugs significantly benefit neurological and behavioral health, including decreased risks of addiction.